Gemphire Therapeutics Inc., of Livonia, Mich., reported preclinical data testing gemcabene in the STAM mouse model of non-alcoholic steatohepatitis (NASH). The highest dose of gemcabene produced a significant histological reduction in the nonalcoholic fatty liver disease activity score.